1.53
前日終値:
$1.51
開ける:
$1.538
24時間の取引高:
8.41M
Relative Volume:
3.18
時価総額:
$1.16B
収益:
$581.12M
当期純損益:
$-212.92M
株価収益率:
-5.588
EPS:
-0.2738
ネットキャッシュフロー:
$-174.22M
1週間 パフォーマンス:
+7.75%
1か月 パフォーマンス:
+18.60%
6か月 パフォーマンス:
+18.60%
1年 パフォーマンス:
+15.91%
Opko Health Inc Stock (OPK) Company Profile
Compare OPK vs TMO, DHR, IDXX, A, NTRA
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
OPK
Opko Health Inc
|
1.53 | 1.14B | 581.12M | -212.92M | -174.22M | -0.2738 |
|
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
|
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-20 | 開始されました | JP Morgan | Neutral |
| 2025-10-31 | ダウングレード | Jefferies | Buy → Hold |
| 2025-04-25 | 開始されました | JP Morgan | Neutral |
| 2023-06-29 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-24 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-11-25 | 開始されました | Piper Jaffray | Overweight |
| 2018-03-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-09-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 繰り返されました | Standpoint Research | Buy |
| 2016-06-03 | 開始されました | Standpoint Research | Buy |
| 2016-03-31 | 繰り返されました | Barrington Research | Outperform |
| 2015-10-16 | 開始されました | JP Morgan | Overweight |
| 2015-09-11 | ダウングレード | Jefferies | Buy → Hold |
| 2015-03-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 繰り返されました | Oppenheimer | Outperform |
| 2014-03-14 | 開始されました | Oppenheimer | Outperform |
| 2013-11-13 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2013-05-30 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-10-22 | 開始されました | Barrington Research | Outperform |
| 2011-12-01 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2011-07-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Opko Health Inc (OPK) 最新ニュース
Price to book forward of OPKO Health, Inc. – FWB:XCY - TradingView
Enterprise value to EBIT forward of Opko Health, Inc. – NASDAQ:OPK - TradingView
Opko Health stock hits 52-week high at 1.6 USD By Investing.com - Investing.com Canada
Enterprise value to EBIT forward of OPKO Health, Inc. – FWB:XCY - TradingView
OPKO Health, Inc. Actuals & Estimates (NASDAQ:OPK) - TradingView
OPKO Health, Inc. Actuals & Estimates (FWB:XCY) - TradingView
OPKO Health, Inc. Actuals & Estimates (TASE:OPK) - TradingView
OPK Forecast — Price Target — Prediction for 2027 - TradingView
OPKO Health (OPK) Stock Could Be 57% Undervalued As Margin Recovery Comes Into Focus - Sahm
OPKO Health Inc (OPK) Institutional Confidence - TradingKey
OPKO Health Inc (OPK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OPKO Health Inc (OPK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Opko Health For: 22 June By Investing.com - Investing.com Nigeria
Director at OPKO (NASDAQ: OPK) receives grant of 60,000 stock options - Stock Titan
OPKO Health (OPK) director receives 30,000-share stock option award at $1.42 - Stock Titan
Opko Health (OPK) director Roger Medel receives 30,000 stock options grant - Stock Titan
Opko Health (OPK) director awarded 30,000 stock options at $1.42 strike - Stock Titan
OPKO HEALTH (OPK) director receives 80,000-share stock option grant - Stock Titan
OPKO Health (OPK) director receives stock options for 30,000 shares - Stock Titan
OPKO Health (OPK) up 17.1% since last earnings report: Can it continue? - MSN
Opko Health Shareholders Back Board, Equity and Auditors - The Globe and Mail
Opko Health shareholders elect board and approve key proposals at annual meeting - Investing.com
OPKO Health (OPK) AGM 2026 Summary - Quartr
OPK: All proposals passed, with robust pipeline progress and $98M remaining for share repurchases - TradingView
OPKO Health Inc (OPK) Valuation: PE, PB & Fair Value Analysis - TradingKey
OPKO Health Inc (OPK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OPKO Health Inc (OPK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OPKO Health Inc (OPK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OPKO Health Inc (OPK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OPKO Health Inc (OPK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Piper Sandler Sticks to Their Buy Rating for Opko Health (OPK) - The Globe and Mail
OPKO Health (OPK) Stock Could Be 58.8% Undervalued After OPK8801001 Preclinical Update - Sahm
OPKO presents preclinical data on acromegaly drug candidate By Investing.com - Investing.com Australia
OPKO presents preclinical data on acromegaly drug candidate - Investing.com
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 - The Manila Times
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
Discover 3 Promising Penny Stocks With Market Caps Over $20M - simplywall.st
Assessing OPKO Health (OPK) Valuation After Expanded Nicoya RAYALDEE Partnership In Greater China - Yahoo Finance
Here's why you should retain OPK stock in your portfolio for now - MSN
How Investors May Respond To OPKO Health (OPK) Boosting Its Nicoya Stake And RAYALDEE Milestones - Yahoo Finance
OPKO Deepens Nicoya Alliance As RAYALDEE China Prospects Draw Focus - Sahm
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
OPK Technical Analysis | Trend, Signals & Chart Patterns | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health (OPK) Jefferies Global Healthcare Conference 2026 Summary - Quartr
OPK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OPKO Health Inc stock (US68375N1037): shares trade steady after recent earnings while valuation stay - AD HOC NEWS
Opko Health Inc (OPK) 財務データ
収益
当期純利益
現金流量
EPS
Opko Health Inc (OPK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
大文字化:
|
ボリューム (24 時間):